You just read:

Insmed Announces Positive Top-Line Results from Phase 2 WILLOW Study of INS1007 in Patients with Non-Cystic Fibrosis Bronchiectasis

News provided by

Insmed Incorporated

Feb 03, 2020, 07:30 ET